Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 1:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Eisai Inc. Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

NCT01525394
View directory record Official record
Conditions
Refractory Solid Tumors, Lymphomas
Interventions
Lenvatinib, Moxifloxacin 400 mg, Placebos (matched to 4 mg and 10 mg lenvatinib capsules).
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Maintenance Intermittent Therapy for Symptomatic GERD Patients

NCT00165841
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Rabeprazole 20 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

NCT00570128
View directory record Official record
Conditions
Down Syndrome
Interventions
Donepezil HCl, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)

NCT00358644
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Decitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
60 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 2Phase 3 Interventional

Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy

NCT00927914
View directory record Official record
Conditions
Mild to Moderate Diabetic Sensorimotor Polyneuropathy
Interventions
Ranirestat, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

NCT02398669
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin hydrochloride
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT04647383
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders
Interventions
Placebo, Lemborexant 10 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Glendale, Arizona • San Diego, California • Brandon, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants

NCT05533801
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lecanemab
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 12, 2026, 1:53 AM EDT
Terminated Phase 2 Interventional Results available

Vaccination Plus Ontak in Patients With Metastatic Melanoma

NCT00515528
View directory record Official record
Conditions
Melanoma
Interventions
4-peptide melanoma vaccine, Ontak
Biological · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 12, 2026, 1:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic

NCT03552107
View directory record Official record
Conditions
Obesity, Weight Loss, Overweight
Interventions
Lorcaserin
Drug
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 12, 2026, 1:53 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

NCT05728736
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Lemborexant 25 mg, Placebo
Drug
Lead sponsor
Brendan Lucey
Other
Eligibility
60 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 1 Interventional Results available

Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

NCT00069277
View directory record Official record
Conditions
Cancer
Interventions
E7389
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Los Angeles, California • Santa Monica, California • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 12, 2026, 1:53 AM EDT
Terminated Phase 3 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

NCT00754052
View directory record Official record
Conditions
Down Syndrome, Cognitive Dysfunction
Interventions
Aricept (donepezil hydrochloride), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
11 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
San Antonio, Texas • Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

NCT00236184
View directory record Official record
Conditions
Heartburn
Interventions
rabeprazole sodium, Placebo
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
19 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2010 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

NCT01289509
View directory record Official record
Conditions
Idiopathic Thrombocytopenia Purpura
Interventions
E5501, Drug: E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 4 Interventional

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

NCT00050999
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome
Interventions
ONTAK
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

KRAS Wild-type Metastatic Colorectal Cancer Trial

NCT00879385
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Dacogen™ (decitabine), Vectibix® (panitumumab)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food-Effect Study of E7386 in Healthy Participants

NCT03996226
View directory record Official record
Conditions
Food Effect in Healthy Participants
Interventions
E7386
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1

NCT06462404
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1)
Interventions
E2086, E2086 Placebo, Active Comparator, Active Comparator Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Santa Ana, California • Miami, Florida • Macon, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 12, 2026, 1:53 AM EDT
Terminated Phase 2 Interventional Results available

Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab

NCT00636805
View directory record Official record
Conditions
Brain Cancer
Interventions
Palonosetron (Aloxi) and Dexamethasone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 12, 2026, 1:53 AM EDT
Active, not recruiting Phase 1 Interventional

Study of E7386 in Participants With Selected Advanced Neoplasms

NCT03264664
View directory record Official record
Conditions
Advanced Neoplasms
Interventions
E7386
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 12, 2026, 1:53 AM EDT
Withdrawn No phase listed Observational

Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme.

NCT00645385
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Interventions
MRS Spectroscopy
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

NCT01328249
View directory record Official record
Conditions
HER2-normal
Interventions
eribulin mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Lebanon, New Hampshire • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 12, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)

NCT00051025
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Lymphoma, B-cell, Lymphoma, Low-grade
Interventions
ONTAK
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Lexington, Kentucky • Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 12, 2026, 1:53 AM EDT